Joris Hemelaar1, Ramyiadarsini Elangovan2, Jason Yun2, Leslie Dickson-Tetteh2, Isabella Fleminger2, Shona Kirtley3, Brian Williams4, Eleanor Gouws-Williams5, Peter D Ghys6. 1. Nuffield Department of Women's & Reproductive Health, Women's Centre, John Radcliffe Hospital, University of Oxford, Oxford, UK. Electronic address: joris.hemelaar@wrh.ox.ac.uk. 2. Nuffield Department of Women's & Reproductive Health, Women's Centre, John Radcliffe Hospital, University of Oxford, Oxford, UK. 3. Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, UK. 4. South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa. 5. Fast-Track Implementation Department, UNAIDS, Geneva, Switzerland. 6. Strategic Information Department, UNAIDS, Geneva, Switzerland.
Abstract
BACKGROUND: Global genetic diversity of HIV-1 is a major challenge to the development of HIV vaccines. We aimed to estimate the regional and global distribution of HIV-1 subtypes and recombinants during 1990-2015. METHODS: We searched PubMed, EMBASE (Ovid), CINAHL (Ebscohost), and Global Health (Ovid) for HIV-1 subtyping studies published between Jan 1, 1990, and Dec 31, 2015. We collected additional unpublished HIV-1 subtyping data through a global survey. We included prevalence studies with HIV-1 subtyping data collected during 1990-2015. We grouped countries into 14 regions and analysed data for four time periods (1990-99, 2000-04, 2005-09, and 2010-15). The distribution of HIV-1 subtypes, circulating recombinant forms (CRFs), and unique recombinant forms (URFs) in individual countries was weighted according to the UNAIDS estimates of the number of people living with HIV (PLHIV) in each country to generate regional and global estimates of HIV-1 diversity in each time period. The primary outcome was the number of samples designated as HIV-1 subtypes A, B, C, D, F, G, H, J, K, CRFs, and URFs. The systematic review is registered with PROSPERO, number CRD42017067164. FINDINGS: This systematic review and global survey yielded 2203 datasets with 383 519 samples from 116 countries in 1990-2015. Globally, subtype C accounted for 46·6% (16 280 897/34 921 639 of PLHIV) of all HIV-1 infections in 2010-15. Subtype B was responsible for 12·1% (4 235 299/34 921 639) of infections, followed by subtype A (10·3%; 3 587 003/34 921 639), CRF02_AG (7·7%; 2 705 110/34 921 639), CRF01_AE (5·3%; 1 840 982/34 921 639), subtype G (4·6%; 1 591 276/34 921 639), and subtype D (2·7%; 926 255/34 921 639). Subtypes F, H, J, and K combined accounted for 0·9% (311 332/34 921 639) of infections. Other CRFs accounted for 3·7% (1 309 082/34 921 639), bringing the proportion of all CRFs to 16·7% (5 844 113/34 921 639). URFs constituted 6·1% (2 134 405/34 921 639), resulting in recombinants accounting for 22·8% (7 978 517/34 921 639) of all global HIV-1 infections. The distribution of HIV-1 subtypes and recombinants changed over time in countries, regions, and globally. At a global level during 2005-15, subtype B increased, subtypes A and D were stable, and subtypes C and G and CRF02_AG decreased. CRF01_AE, other CRFs, and URFs increased, leading to a consistent increase in the global proportion of recombinants over time. INTERPRETATION: Global and regional HIV diversity is complex and evolving, and is a major challenge to HIV vaccine development. Surveillance of the global molecular epidemiology of HIV-1 remains crucial for the design, testing, and implementation of HIV vaccines. FUNDING: None.
BACKGROUND: Global genetic diversity of HIV-1 is a major challenge to the development of HIV vaccines. We aimed to estimate the regional and global distribution of HIV-1 subtypes and recombinants during 1990-2015. METHODS: We searched PubMed, EMBASE (Ovid), CINAHL (Ebscohost), and Global Health (Ovid) for HIV-1 subtyping studies published between Jan 1, 1990, and Dec 31, 2015. We collected additional unpublished HIV-1 subtyping data through a global survey. We included prevalence studies with HIV-1 subtyping data collected during 1990-2015. We grouped countries into 14 regions and analysed data for four time periods (1990-99, 2000-04, 2005-09, and 2010-15). The distribution of HIV-1 subtypes, circulating recombinant forms (CRFs), and unique recombinant forms (URFs) in individual countries was weighted according to the UNAIDS estimates of the number of people living with HIV (PLHIV) in each country to generate regional and global estimates of HIV-1 diversity in each time period. The primary outcome was the number of samples designated as HIV-1 subtypes A, B, C, D, F, G, H, J, K, CRFs, and URFs. The systematic review is registered with PROSPERO, number CRD42017067164. FINDINGS: This systematic review and global survey yielded 2203 datasets with 383 519 samples from 116 countries in 1990-2015. Globally, subtype C accounted for 46·6% (16 280 897/34 921 639 of PLHIV) of all HIV-1 infections in 2010-15. Subtype B was responsible for 12·1% (4 235 299/34 921 639) of infections, followed by subtype A (10·3%; 3 587 003/34 921 639), CRF02_AG (7·7%; 2 705 110/34 921 639), CRF01_AE (5·3%; 1 840 982/34 921 639), subtype G (4·6%; 1 591 276/34 921 639), and subtype D (2·7%; 926 255/34 921 639). Subtypes F, H, J, and K combined accounted for 0·9% (311 332/34 921 639) of infections. Other CRFs accounted for 3·7% (1 309 082/34 921 639), bringing the proportion of all CRFs to 16·7% (5 844 113/34 921 639). URFs constituted 6·1% (2 134 405/34 921 639), resulting in recombinants accounting for 22·8% (7 978 517/34 921 639) of all global HIV-1 infections. The distribution of HIV-1 subtypes and recombinants changed over time in countries, regions, and globally. At a global level during 2005-15, subtype B increased, subtypes A and D were stable, and subtypes C and G and CRF02_AG decreased. CRF01_AE, other CRFs, and URFs increased, leading to a consistent increase in the global proportion of recombinants over time. INTERPRETATION: Global and regional HIV diversity is complex and evolving, and is a major challenge to HIV vaccine development. Surveillance of the global molecular epidemiology of HIV-1 remains crucial for the design, testing, and implementation of HIV vaccines. FUNDING: None.
Authors: Stella J Berendam; Tiffany M Styles; Rama R Amara; Genevieve G Fouda; Papa K Morgan-Asiedu; DeAnna Tenney; Amit Kumar; Veronica Obregon-Perko; Katharine J Bar; Kevin O Saunders; Sampa Santra; Kristina De Paris; Georgia D Tomaras; Ann Chahroudi; Sallie R Permar Journal: J Virol Date: 2021-01-13 Impact factor: 5.103
Authors: Christina Ekenberg; Man-Hung Tang; Adrian G Zucco; Daniel D Murray; Cameron Ross MacPherson; Xiaojun Hu; Brad T Sherman; Marcelo H Losso; Robin Wood; Roger Paredes; Jean-Michel Molina; Marie Helleberg; Nureen Jina; Cissy M Kityo; Eric Florence; Mark N Polizzotto; James D Neaton; H Clifford Lane; Jens D Lundgren Journal: J Infect Dis Date: 2019-09-13 Impact factor: 5.226
Authors: David A Spencer; Delphine C Malherbe; Néstor Vázquez Bernat; Monika Ádori; Benjamin Goldberg; Nicholas Dambrauskas; Heidi Henderson; Shilpi Pandey; Tracy Cheever; Philip Barnette; William F Sutton; Margaret E Ackerman; James J Kobie; D Noah Sather; Gunilla B Karlsson Hedestam; Nancy L Haigwood; Ann J Hessell Journal: J Immunol Date: 2021-01-20 Impact factor: 5.422
Authors: Jenna Weber; Ilona Volkova; Malaya K Sahoo; Philip L Tzou; Robert W Shafer; Benjamin A Pinsky Journal: J Mol Diagn Date: 2019-08-02 Impact factor: 5.568
Authors: Adam A Capoferri; Susanna L Lamers; Mary Kate Grabowski; Rebecca Rose; Maria J Wawer; David Serwadda; Ronald H Gray; Thomas C Quinn; Godfrey Kigozi; Joseph Kagaayi; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2020-03-02 Impact factor: 2.205
Authors: Athena Chen; Oliver Laeyendecker; Susan H Eshleman; Daniel R Monaco; Kai Kammers; Harry Benjamin Larman; Ingo Ruczinski Journal: Stat Med Date: 2021-03-03 Impact factor: 2.373
Authors: Ronald Moses Galiwango; Charles Ssuuna; Pontiano Kaleebu; Godfrey Kigozi; Joseph Kagaayi; Gertrude Nakigozi; Steven James Reynolds; Tom Lutalo; Edward Nelson Kankaka; John Bosco Wasswa; Sarah N Kalibbala; Aminah N Kigozi; Christine Watera; Julia Ejang; Anthony Ndyanabo; Aggrey J Anok; Deogratius Ssemwanga; Freddie M Kibengo; Thomas C Quinn; Mary Grabowski; Larry W Chang; Maria Wawer; Ronald Gray; Oliver Laeyendecker; David Serwadda Journal: AIDS Res Hum Retroviruses Date: 2021-02-25 Impact factor: 2.205